|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XX54
|
|
gptkbp:CASNumber
|
1038915-60-4
|
|
gptkbp:chemicalFormula
|
C19H20N4O
|
|
gptkbp:contraindication
|
hypersensitivity to niraparib
|
|
gptkbp:drugClass
|
PARP inhibitor
|
|
gptkbp:genericName
|
niraparib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zejula
|
|
gptkbp:indication
|
maintenance treatment of recurrent ovarian cancer
first-line maintenance treatment in advanced ovarian cancer
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits PARP enzymes
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
gptkb:acute_myeloid_leukemia
hypertension
myelodysplastic syndrome
bone marrow suppression
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
constipation
fatigue
thrombocytopenia
|
|
gptkbp:UNII
|
3XNW2WA2W5
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:fallopian_tube_cancer
primary peritoneal cancer
|
|
gptkbp:bfsParent
|
gptkb:SF-2281
|
|
gptkbp:bfsLayer
|
7
|